Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: Results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial

American Heart Journal

Volumn 144, Issue 1, 2002, Pages 60-67

  Lee, Douglas S ^a   Goodman, Shaun ^a,b   Dean, Deanne M ^c   Lenis, Jacques ^d   Ma, Patrick ^d   Gervais, Pierre B ^d   Langer, Anatoly ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c Hoffman La Roche Canada   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DILTIAZEM; MIBEFRADIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; TREADMILL EXERCISE; VERTIGO;

EID: 0036308997     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.122869     Document Type: Article

References (42)

1. Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing
2. Superiority of verapamil to propranolol in stable angina pectoris: A double-blind, randomized crossover trial
3. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial
4. Calcium channel blocking agents in the treatment of cardiovascular disorders: Hemodynamic effects and clinical applications
5. Calcium-channel antagonists: Mechanisms of action, vascular selectivities, and clinical relevance
6. Lack of negative inotropic effects of a new calcium antagonist Ro 40-5967 in patients with stable angina pectoris
7. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil
8. Mibefradil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris
9. Protein families that mediate Ca signaling in the cardiovascular system
10. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: Potential indications for T-type calcium antagonists
11. Mibefradil: A selective T-type calcium antagonist
12. T-type Ca current is expressed in hypertrophied adult feline left ventricular myocytes
13. Cardiovascular T-type calcium channels: Physiological and pharmacological significance
14. The relevance of T-type calcium antagonists: A profile of mibefradil
15. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension
16. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists?
17. Withdrawal of posicor from market
18. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
19. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study
20. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia
21. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled randomized comparison with sustained-release diltiazem
22. Aging, autonomic function, and the perception of angina
23. Variability of indexes for myocardial ischemia: A comparison of exercise treadmill test, ambulatory electrocardiographic monitoring and symptoms of myocardial ischemia
24. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: Maintenance of ventricular fibrillation threshold without inotropic compromise
25. The effects of mibefradil, a novel calcium channel antagonist, on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation
26. Unique cardioprotective action of the new calcium antagonist mibefradil
27. Good news for experimental concept but bad news for clinically effective therapy
28. Rhabdomyolysis due to interaction of simvastatin with mibefradil
29. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
30. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction
31. Increased survival after long-term treatment with mibefradil, an elective T-channel calcium antagonist, in heart failure
32. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats
33. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: The MACH-1 study
34. Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris
35. Use of exercise test parameters to predict presence and duration of ambulatory ischemia in patients with coronary artery disease
36. Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker
37. Intermittent transdermal nitroglycerin therapy in angina pectoris: Clinically effective without tolerance or rebound
38. Acute and chronic antionginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin
39. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina
40. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem